Association between metabolic dysfunction associated steatotic liver disease and gallstones in the US population using propensity score matching
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Янв. 6, 2025
The
novel
diagnostic
term
Metabolic
Dysfunction-Associated
Steatotic
Liver
Disease
(MASLD)
requires
at
least
one
cardiovascular
risk
factor
for
diagnosis.
While
the
relationship
between
gallstones
and
Non-Alcoholic
Fatty
(NAFLD)
has
been
debated,
association
MASLD
remains
unclear.
This
cross-sectional
study
aimed
to
explore
this
using
National
Health
Nutrition
Examination
Survey
(NHANES)
data
from
2017
2020.
Participants
were
stratified
into
two
groups
based
on
diagnosis,
propensity
score
matching
(PSM)
was
employed
reduce
biases.
Of
15,560
participants,
7922
met
inclusion
criteria,
with
2697
(34.0%)
diagnosed
MASLD.
Gallstone
prevalence
higher
in
group
(14.2%)
compared
non-MASLD
(8.5%).
After
PSM,
4536
participants
analyzed,
revealing
a
significant
(OR
=
1.30,
95%
CI
1.09–1.56,
P
0.003).
remained
robust
across
crude
adjusted
analyses,
subgroup
sensitivity
analyses
further
supporting
findings.
In
conclusion,
is
significantly
associated
an
increased
of
US
population.
These
findings
highlight
need
consider
clinical
strategies
prevention
management
gallstone
disease.
Язык: Английский
The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study
Pharmaceuticals,
Год журнала:
2025,
Номер
18(1), С. 129 - 129
Опубликована: Янв. 19, 2025
Background/Objectives:
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
an
important
common
comorbidity
in
subjects
with
type
2
diabetes,
and
fibrosis
a
factor
directly
related
to
its
prognosis.
Glucagon-like
peptide-1
receptor
agonists
are
useful
treatment
options
for
MASLD;
however,
the
efficacy
of
oral
semaglutide
treating
steatosis/fibrosis
has
not
been
fully
elucidated.
Methods:
A
secondary
analysis
multicenter,
retrospective,
observational
study
investigating
safety
Japanese
diabetes
real-world
clinical
setting
(the
Sapporo-Oral
SEMA
study)
was
conducted.
Subjects
original
cohort
were
divided
into
groups
as
follows:
suspected
MASLD
(alanine
aminotransferase
>
30
U/L)
placed
overall
group;
subpopulation
from
group
at
high
risk
hepatic
(fibrosis-4
(FIB-4)
index
≥
1.3
or
platelet
count
<
200,000/µL)
high-risk
remaining
low-risk
group.
Changes
steatosis
FIB-4
after
induction
explored
using
paired
t-test
Wilcoxon
signed-rank
test.
Results:
Overall,
169
(including
131
that
switched
other
medications)
analyzed,
67
102
selected
groups,
respectively.
Oral
significantly
improved
(from
46.1
44.6,
p
0.001)
1.04
0.96,
well
several
metabolic
parameters
all
cohorts.
The
confirmed
by
addition
of,
switching
from,
existing
agent
groups.
Furthermore,
improvement
negatively
correlated
baseline
index.
Conclusions:
might
be
option
fibrosis,
even
when
conventional
medications
diabetes.
Язык: Английский
Metabolic outcomes in non-alcoholic and alcoholic steatotic liver disease among Korean and American adults
BMC Gastroenterology,
Год журнала:
2025,
Номер
25(1)
Опубликована: Фев. 24, 2025
This
study
investigated
the
prevalence
and
causal
relationships
of
chronic
metabolic
diseases
(diabetes,
hypertension,
dyslipidemia)
with
steatotic
liver
disease
(SLD),
specifically
metabolically
associated
alcoholic
(MetALD).
We
conducted
a
comprehensive
analysis
using
cross-sectional
data
from
KNHANES
2011
to
2021
NHANES
1999
2020.
Longitudinal
2001
2014
KoGES
were
used.
Participants
categorized
into
dysfunction-associated
SLD(MASLD),
MetALD,
ALD
groups
based
on
their
hepatic
steatosis
index
(HSI),
including
profiles,
body
composition,
diabetes,
alcohol
consumption.
Multivariable,
age
smoking
status,
logistic
Cox
regression
analyses
performed
assess
incidence
diseases.
In
both
cohorts,
an
increased
HSI
was
significantly
higher
cohort
showed
that
MASLD
MetALD
significant
predictors
in
men
women.
hazard
ratio
for
development
than
analysis.
highlighted
intertwined
nature
SLD
health,
emphasis
role
MetALD.
The
association
between
underscores
need
integrated
management
strategies
address
health
risk
factors.
Язык: Английский
High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction
Biomolecules,
Год журнала:
2024,
Номер
14(11), С. 1468 - 1468
Опубликована: Ноя. 18, 2024
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
a
recently
introduced
term
for
(SLD).
Although
the
inflammatory
process
central
to
pathogenesis
of
SLD,
research
investigating
differences
in
systemic
inflammation
across
various
SLD
subtypes
as
well
sex
limited.
This
population-based,
cross-sectional
study
investigated
association
between
and
high-sensitivity
C-reactive
protein
(hs-CRP)
levels
among
Korean
adults
(N
=
20,141;
mean
age:
50.8
±
16.7
years).
The
participants
were
classified
into
five
groups
that
included
no
MASLD,
metabolic
alcohol-associated
(MetALD),
alcoholic
with
dysfunction
(ALD
MD),
other
SLDs.
median
(Q1,
Q3)
value
hs-CRP
level
was
0.54
mg/L
(0.33,
1.04).
Among
men,
compared
group,
MetALD,
ALD
MD
associated
41.9%
(95%
confidence
interval
[CI]:
35.1-49.1%),
46.8%
CI:
35.0-59.6%),
51.8%
30.0-77.2%)
increases
levels,
respectively.
stronger
women,
81.5%
73.6-89.8%),
84.3%
58.1-114.8%),
98.2%
38.0-184.8%)
In
conclusion,
our
findings
indicate
varying
profile
subtypes,
more
pronounced
women
Язык: Английский
Coexisting metabolic dysfunction-associated steatotic liver disease exacerbates in-hospital outcomes in patients with heat stroke
Frontiers in Medicine,
Год журнала:
2024,
Номер
11
Опубликована: Ноя. 12, 2024
Purpose
This
study
aimed
to
investigate
the
impact
of
coexisting
metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
on
in-hospital
mortality
and
organ
injury
markers
in
patients
with
heat
stroke
(HS).
Approach
HS
were
retrospectively
identified
between
July
1,
2022
September
30,
2023
at
West
China
Hospital,
Sichuan
University.
Baseline
characteristics,
such
as
demographics,
initial
vital
signs,
functional
indicators
collected.
Outcome
events
included
mortality.
The
Least
Absolute
Shrinkage
Selection
Operator
(Lasso)
method
was
employed
identify
optimal
predictors
for
patients.
Subsequently,
multivariable
logistic
regression
analysis
performed
assess
relationship
presence
MASLD
well
function
indicators.
Findings
A
total
112
study,
which
27
(24.1%)
had
MASLD.
Compared
those
without
MASLD,
higher
levels
various
aspartate
aminotransferase,
urea
nitrogen,
serum
cystatin
C,
creatinine,
uric
acid,
myoglobin,
creatine
kinase
its
isoenzymes
upon
admission
(
P
<
0.05).
Logistic
indicated
that
is
an
independent
risk
factor
Conclusion
firstly
may
exacerbate
serve
Язык: Английский